A small multi-center clinical trial in patients with relapsed or refractory IDH1 mutated gliomas observed no dose-limiting toxicity and provided preliminary evidence for effective brain penetration and therapeutic efficacy of FT-2102 [103], although these results need to be confirmed by further studies. This evidence concerns the gene IDH1 and glioma.